Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy

Cancer Gene Therapy volume 14, pages 1–11 (2007)Cite this article

Abstract

Bcl-2 is an oncoprotein that plays a critical role in inhibiting apoptotic cell death in the mitochondria-dependent pathway in cancer chemotherapy. As a strategy for blocking Bcl-2 for enhancement of the chemotherapeutic effect, antisense Bcl-2 (AS Bcl-2; G3139, oblimersen sodium, Genasense) has shown promise, and there are several ongoing clinical studies with hematological malignancies as well as solid tumors. Although several preclinical and clinical studies have shown the therapeutic efficacy of Bcl-2 in combination with an anticancer drug as a chemosensitizer, in clinical trials the downregulation of Bcl-2 has not been observed with a high frequency in tumor cells. Nevertheless, previous studies showed nonantisense effects such as production of reactive oxygen species and immunostimulatory action through cytosine-phosphate-guanosine-motif in the antisense oligodeoxynucleotides. Further, Bcl-2 is able to inhibit Beclin 1-dependent autophagic cell death, which is a nonapoptotic cell death. The current status and future directions of AS Bcl-2 and the potential mechanisms for multiple roles that Bcl-2 has in cancer therapy are reviewed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Tsujimoto Y, Cossman J, Jaffe E, Croce CM . Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228: 1440–1443.

    Article  CAS  PubMed  Google Scholar 

  2. Vaux DL, Cory S, Adams JM . Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440–442.

    Article  CAS  PubMed  Google Scholar 

  3. Perego P, Righetti SC, Supino R, Delia D, Caserini C, Carenini N et al. Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines. Apoptosis 1997; 2: 540–548.

    Article  CAS  PubMed  Google Scholar 

  4. Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ et al. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 2003; 63: 312–318.

    CAS  PubMed  Google Scholar 

  5. Reed JC . Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997; 34 (4 Suppl 5): 9–19.

    CAS  PubMed  Google Scholar 

  6. Biroccio A, Del Bufalo D, Fanciulli M, Bruno T, Zupi G, Floridi A . bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant MCF7 cells. Int J Cancer 1999; 82: 125–130.

    Article  CAS  PubMed  Google Scholar 

  7. Ushmorov A, Ratter F, Lehmann V, Droge W, Schirrmacher V, Umansky V . Nitric-oxide-induced apoptosis in human leukemic lines requires mitochondrial lipid degradation and cytochrome c release. Blood 1999; 93: 2342–2352.

    CAS  PubMed  Google Scholar 

  8. Hua C, Raffeld M, Ko HS, Fast P, Bakhshi A, Cossman J . Mechanism of bcl-2 activation in human follicular lymphoma. Oncogene 1990; 5: 233–235.

    CAS  PubMed  Google Scholar 

  9. Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC . Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol 2003; 4: 211–218.

    Article  PubMed  Google Scholar 

  10. Coultas L, Strasser A . The role of the Bcl-2 protein family in cancer. Semin Cancer Biol 2003; 13: 115–123.

    Article  CAS  PubMed  Google Scholar 

  11. Chanan-Khan A . Bcl-2 antisense therapy in B-cell malignancies. Blood Rev 2005; 19: 213–221.

    Article  CAS  PubMed  Google Scholar 

  12. Armstrong JS . Mitochondria: a target for cancer therapy. Br J Pharmacol 2005; 147: 239–248.

    Article  PubMed Central  Google Scholar 

  13. Lucken-Ardjomande S, Martinou JC . Regulation of Bcl-2 proteins and of the permeability of the outer mitochondrial membrane. C R Biol 2005; 328: 616–631.

    Article  CAS  PubMed  Google Scholar 

  14. Hail Jr N . Mitochondria: a novel target for the chemoprevention of cancer. Apoptosis 2005; 10: 687–705.

    Article  CAS  PubMed  Google Scholar 

  15. Kim R . Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 2005; 103: 1551–1560.

    Article  CAS  PubMed  Google Scholar 

  16. Bouchier-Hayes L, Lartigue L, Newmeyer DD . Mitochondria: pharmacological manipulation of cell death. J Clin Invest 2005; 115: 2640–2647.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Mikhailov V, Mikhailova M, Degenhardt K, Venkatachalam MA, White E, Saikumar P . Association of Bax and Bak homo-oligomers in mitochondria. Bax requirement for Bak reorganization and cytochrome c release. J Biol Chem 2003; 278: 5367–5376.

    Article  CAS  PubMed  Google Scholar 

  18. Tolcher AW . Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides. Clin Adv Hematol Oncol 2005; 3: 635–642, 662.

    PubMed  Google Scholar 

  19. De Cesare M, Perego P, Righetti SC, Pratesi G, Carenini N, Rivoltini L et al. Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts. Eur J Cancer 2005; 41: 1213–1222.

    Article  CAS  PubMed  Google Scholar 

  20. Emi M, Kim R, Tanabe K, Uchida Y, Toge T . Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res 2005; 7: R940–R952.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kim R, Emi M, Tanabe K, Toge T . Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma. Cancer 2004; 101: 2177–2186.

    Article  CAS  PubMed  Google Scholar 

  22. Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD . Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 2000; 6: 2891–2902.

    CAS  PubMed  Google Scholar 

  23. Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003; 101: 425–432.

    Article  CAS  PubMed  Google Scholar 

  24. Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I et al. A phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2004; 10: 5048–5057.

    Article  CAS  PubMed  Google Scholar 

  25. Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y et al. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 2004; 15: 1274–1283.

    Article  CAS  PubMed  Google Scholar 

  26. Rudin CM, Otterson GA, Mauer AM, Villalona-Calero MA, Tomek R, Prange B et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002; 13: 539–545.

    Article  CAS  PubMed  Google Scholar 

  27. Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004; 22: 1110–1117.

    Article  CAS  PubMed  Google Scholar 

  28. Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002; 8: 679–683.

    CAS  PubMed  Google Scholar 

  29. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 3920–3927.

    CAS  PubMed  Google Scholar 

  30. Kirkwood JM, Bedikian AY, Millward MJ, Conry RM, Gore ME, Pehamberger HE et al. Long-term survival results of randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients with advanced malignant melanoma. Proc Annu Meeting ASCO 2005; 23 (16S): 711s.

    Google Scholar 

  31. Stein CA, Benimetskaya L, Mani S . Antisense strategies for oncogene inactivation. Semin Oncol 2005; 32: 563–572.

    Article  CAS  PubMed  Google Scholar 

  32. Letai A . Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest 2005; 115: 2648–2655.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wacheck V, Krepler C, Strommer S, Heere-Ress E, Klem R, Pehamberger H et al. Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice. Antisense Nucleic Acid Drug Dev 2002; 12: 359–367.

    Article  CAS  PubMed  Google Scholar 

  34. Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B et al. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 2005; 23: 4089–4099.

    Article  CAS  PubMed  Google Scholar 

  35. Du C, Fang M, Li Y, Li L, Wang X . Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33–42.

    Article  CAS  PubMed  Google Scholar 

  36. Song Z, Yao X, Wu M . Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003; 278: 23130–23140.

    Article  CAS  PubMed  Google Scholar 

  37. Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y . Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000; 406: 855–862.

    Article  CAS  PubMed  Google Scholar 

  38. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397: 441–446.

    Article  CAS  PubMed  Google Scholar 

  39. Clement MV, Hirpara JL, Pervaiz S . Decrease in intracellular superoxide sensitizes Bcl-2-overexpressing tumor cells to receptor and drug-induced apoptosis independent of the mitochondria. Cell Death Differ 2003; 10: 1273–1285.

    Article  CAS  PubMed  Google Scholar 

  40. Lai JC, Benimetskaya L, Santella RM, Wang Q, Miller PS, Stein CA . G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Mol Cancer Ther 2003; 2: 1031–1043.

    CAS  PubMed  Google Scholar 

  41. Raffo A, Lai JC, Stein CA, Miller P, Scaringe S, Khvorova A et al. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen). Clin Cancer Res 2004; 10: 3195–3206.

    Article  CAS  PubMed  Google Scholar 

  42. Kolenko VM, Uzzo RG, Bukowski R, Finke JH . Caspase-dependent and -independent death pathways in cancer therapy. Apoptosis 2000; 5: 17–20.

    Article  CAS  PubMed  Google Scholar 

  43. Levine B, Yuan J . Autophagy in cell death: an innocent convict? J Clin Invest 2005; 115: 2679–2688.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Mizushima N . The pleiotropic role of autophagy: from protein metabolism to bactericide. Cell Death Differ 2005; 12: 1535–1541.

    Article  CAS  PubMed  Google Scholar 

  45. Aita VM, Liang XH, Murty VV, Pincus DL, Yu W, Cayanis E et al. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 1999; 59: 59–65.

    Article  CAS  PubMed  Google Scholar 

  46. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999; 402: 672–676.

    Article  CAS  PubMed  Google Scholar 

  47. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005; 122: 927–939.

    Article  CAS  PubMed  Google Scholar 

  48. Saeki K, Yuo A, Okuma E, Yazaki Y, Susin SA, Kroemer G et al. Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells. Cell Death Differ 2000; 7: 1263–1269.

    Article  CAS  PubMed  Google Scholar 

  49. Tracey L, Perez-Rosado A, Artiga MJ, Camacho FI, Rodriguez A, Martinez N et al. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol 2005; 206: 123–134.

    Article  CAS  PubMed  Google Scholar 

  50. Choi J, Choi K, Benveniste EN, Hong YS, Lee JH, Kim J et al. Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2. Cancer Res 2005; 65: 5554–5560.

    Article  CAS  PubMed  Google Scholar 

  51. Biroccio A, Candiloro A, Mottolese M, Sapora O, Albini A, Zupi G et al. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J 2000; 14: 652–660.

    Article  CAS  PubMed  Google Scholar 

  52. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096–1103.

    Article  CAS  PubMed  Google Scholar 

  53. Jahrsdorfer B, Jox R, Muhlenhoff L, Tschoep K, Krug A, Rothenfusser S et al. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 2002; 72: 83–92.

    CAS  PubMed  Google Scholar 

  54. Wiemann B, Starnes CO . Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994; 64: 529–564.

    Article  CAS  PubMed  Google Scholar 

  55. Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984; 72: 955–962.

    CAS  PubMed  Google Scholar 

  56. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546–549.

    Article  CAS  PubMed  Google Scholar 

  57. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740–745.

    Article  CAS  PubMed  Google Scholar 

  58. Krieg AM . CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709–760.

    Article  CAS  PubMed  Google Scholar 

  59. Greenwald RJ, Freeman GJ, Sharpe AH . The B7 family revisited. Annu Rev Immunol 2005; 23: 515–548.

    Article  PubMed  Google Scholar 

  60. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004; 34: 251–262.

    Article  CAS  PubMed  Google Scholar 

  61. Duramad O, Fearon KL, Chan JH, Kanzler H, Marshall JD, Coffman RL et al. IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. Blood 2003; 102: 4487–4492.

    Article  CAS  PubMed  Google Scholar 

  62. Kim R, Emi M, Tanabe K . Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol Ther 2005; 4: 924–933.

    Article  CAS  PubMed  Google Scholar 

  63. Zou W, Machelon V, Coulomb-L’Hermin A, Borvak J, Nome F, Isaeva T et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7: 1339–1346.

    Article  CAS  PubMed  Google Scholar 

  64. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003; 170: 4905–4913.

    Article  CAS  PubMed  Google Scholar 

  65. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004; 53: 64–72.

    Article  CAS  PubMed  Google Scholar 

  66. Kusmartsev S, Gabrilovich DI . Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002; 51: 293–298.

    Article  CAS  PubMed  Google Scholar 

  67. Benimetskaya L, Wittenberger T, Stein CA, Hofmann HP, Weller C, Lai JC et al. Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma. Clin Cancer Res 2004; 10: 3678–3688.

    Article  CAS  PubMed  Google Scholar 

  68. Kaubisch A, Wu Y-H, Wadler S . Phase I/II study of genasense (G3139) in combination with cisplatin and fluorouracil in patients with advanced esophageal, gastro-esophageal junction and gastric cancer. Proc Annu Meeting ASCO 2005; 884s.

  69. Mays TA, Mita AC, Takimoto C, Petro D, Egorin MJ, Patnaik A et al. Bcl-2 biomodulation with oblimersen sodium in combination with FOLFOX4 chemotherapy: a phase I study in metastatic colon carcinoma. Proc Annu Meeting ASCO 2005; 24: 231s.

    Google Scholar 

  70. Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA et al. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense™, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol 2006; 17: 313–321.

    Article  CAS  PubMed  Google Scholar 

  71. Fisher G, Advani R, Wakelee H, Jacobs C, Gladysheva K, Fitzgerald AM et al. A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies. Proc Annu Meeting ASCO 2005; 23 (16S): 234s.

    Google Scholar 

  72. Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11: 3854–3861.

    Article  CAS  PubMed  Google Scholar 

  73. Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ et al. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2004; 15: 915–920.

    Article  CAS  PubMed  Google Scholar 

  74. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002; 99: 4079–4086.

    Article  CAS  PubMed  Google Scholar 

  75. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC . Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998; 95: 4997–5002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. van de Donk NW, de Weerdt O, Veth G, Eurelings M, van Stralen E, Frankel SR et al. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia 2004; 18: 1078–1084.

    Article  CAS  PubMed  Google Scholar 

  77. Sawada S, Mese H, Sasaki A, Yoshioka N, Matsumura T . Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line. Cancer Chemother Pharmacol 2003; 51: 505–511.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    R Kim

  2. Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    M Emi, K Matsuura & K Tanabe

Authors
  1. R Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Emi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Matsuura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Tanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, R., Emi, M., Matsuura, K. et al. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Ther 14, 1–11 (2007). https://doi.org/10.1038/sj.cgt.7700986

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700986

Keywords

This article is cited by

Search

Advanced search

Quick links